Anthrax – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Anthrax – Pipeline Review, H1 2020’, provides an overview of the Anthrax pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anthrax, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anthrax and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Anthrax

– The report reviews pipeline therapeutics for Anthrax by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Anthrax therapeutics and enlists all their major and minor projects

– The report assesses Anthrax therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Anthrax

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Anthrax

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Anthrax pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Altimmune Inc

Aphios Corp

Aradigm Corp

Biologics Resources LLC

BlueWillow Biologics Inc

Companhia Industrial Produtora de Antibioticos SA

Crestone Inc

Dynavax Technologies Corp

Elusys Therapeutics Inc

Emergent BioSolutions Inc

GC Pharma

Greffex Inc

Hawaii Biotech Inc

iBio Inc

Innovative Biologics Inc

Integrated BioTherapeutics Inc

iNtRON Biotechnology Inc

Opal Biosciences Ltd

Protein Potential LLC

ProThera Biologics Inc

Soligenix Inc

Tetraphase Pharmaceuticals Inc

Vast Therapeutics Inc

Venomyx Inc

VLP Biotech Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Anthrax - Overview

Anthrax - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Anthrax - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Anthrax - Companies Involved in Therapeutics Development

Altimmune Inc

Aphios Corp

Aradigm Corp

Biologics Resources LLC

BlueWillow Biologics Inc

Companhia Industrial Produtora de Antibioticos SA

Crestone Inc

Dynavax Technologies Corp

Elusys Therapeutics Inc

Emergent BioSolutions Inc

GC Pharma

Greffex Inc

Hawaii Biotech Inc

iBio Inc

Innovative Biologics Inc

Integrated BioTherapeutics Inc

iNtRON Biotechnology Inc

Opal Biosciences Ltd

Protein Potential LLC

ProThera Biologics Inc

Soligenix Inc

Tetraphase Pharmaceuticals Inc

Vast Therapeutics Inc

Venomyx Inc

VLP Biotech Inc

Anthrax - Drug Profiles

Anthrax - Dormant Projects

Anthrax - Discontinued Products

Anthrax - Product Development Milestones

Featured News & Press Releases

Appendix

List of Tables

List of Tables

Number of Products under Development for Anthrax, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Anthrax – Pipeline by Altimmune Inc, H1 2020

Anthrax – Pipeline by Aphios Corp, H1 2020

Anthrax – Pipeline by Aradigm Corp, H1 2020

Anthrax – Pipeline by Biologics Resources LLC, H1 2020

Anthrax – Pipeline by BlueWillow Biologics Inc, H1 2020

Anthrax – Pipeline by Companhia Industrial Produtora de Antibioticos SA, H1 2020

Anthrax – Pipeline by Crestone Inc, H1 2020

Anthrax – Pipeline by Dynavax Technologies Corp, H1 2020

Anthrax – Pipeline by Elusys Therapeutics Inc, H1 2020

Anthrax – Pipeline by Emergent BioSolutions Inc, H1 2020

Anthrax – Pipeline by GC Pharma, H1 2020

Anthrax – Pipeline by Greffex Inc, H1 2020

Anthrax – Pipeline by Hawaii Biotech Inc, H1 2020

Anthrax – Pipeline by iBio Inc, H1 2020

Anthrax – Pipeline by Innovative Biologics Inc, H1 2020

Anthrax – Pipeline by Integrated BioTherapeutics Inc, H1 2020

Anthrax – Pipeline by iNtRON Biotechnology Inc, H1 2020

Anthrax – Pipeline by Opal Biosciences Ltd, H1 2020

Anthrax – Pipeline by Protein Potential LLC, H1 2020

Anthrax – Pipeline by ProThera Biologics Inc, H1 2020

Anthrax – Pipeline by Soligenix Inc, H1 2020

Anthrax – Pipeline by Tetraphase Pharmaceuticals Inc, H1 2020

Anthrax – Pipeline by Vast Therapeutics Inc, H1 2020

Anthrax – Pipeline by Venomyx Inc, H1 2020

Anthrax – Pipeline by VLP Biotech Inc, H1 2020

Anthrax – Dormant Projects, H1 2020

Anthrax – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Anthrax, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports